SS
AIMT

Steve Schonfeld’s Aimmune Therapeutics AIMT Stock Holding History

Steve Schonfeld’s Portfolio AIMT Stock Details AIMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-19,840
Closed -$407K – 843
2017
Q2 		$407K Buy
+19,840
New +$378K 0.04% 426

Other funds holding AIMT

FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
AC
Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
TG
TLP Group Evanston, Illinois $6.61M AUM 12.46% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Steve Schonfeld's AIMT Position: Q3 2017 in Review

Steve Schonfeld sold out of Aimmune Therapeutics (AIMT) in Q3 2017, closing a stake of 19,840 shares — an estimated $407K sold.

Steve Schonfeld first reported a position in AIMT in Q2 2017 and held it in 1 quarter. The position peaked at $407K in Q2 2017. 100 funds tracked by Wall St. Rank hold AIMT as of Q3 2017.

  • Steve Schonfeld reported no remaining Aimmune Therapeutics position as of Q3 2017 after selling out during the quarter.
  • Steve Schonfeld sold 19,840 Aimmune Therapeutics shares in Q3 2017, an estimated $407K.
  • Steve Schonfeld first reported a position in Aimmune Therapeutics in Q2 2017 and held it in 1 quarter.
  • Steve Schonfeld's Aimmune Therapeutics position peaked at $407K in Q2 2017.
  • 100 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q3 2017.

Based on Schonfeld Strategic Advisors's 13F filing for Q3 2017, filed 14 Nov 2017.